Evaluation of efficacy and mechanisms of action of Cannabis sativa extracts with analgesic, anti-inflammatory and antiemetic properties in an in vivo model
AbstractUniversity of Medical Sciences participates in the realization of the project titled: „Development of the technology of producing cannabinoids from low THC hemp for use as preparations supporting treatment in oncological patients” awarded by the National Centre for Research and Development under project number: INNOMED/I/11/NCBR/2014. The duration of the grant is 36 months, and the total value of the grant is 28011845 PLN. The project is run by University of Life Sciences in Poznan. Laboratory of Experimental Pharmacogenetics at the Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences (PUMS) is realizing the task number 4 titled “Evaluation of efficacy and mechanisms of action of Cannabis sativa extracts with analgesic, anti-inflammatory and antiemetic properties in an in vivo model.” The aim of this project is the development of cannabinoid extract with reduced psychoactive component (THC), which due to its high content of cannabidiol (CBD) is meant to provide analgesic properties, and at the same time to reduce the risk of addiction and overdose. University of Medical Sciences is evaluating the analgesic, anti-inflammatory and antiemetic properties of the extract of Cannabis sativa in animal models coupled with neuropathic pain. Pharmacodynamic effects of plant extracts will be later assessed taking into account the level of selected genes and proteins expression.
Aley KO, Rechling DB, Levine JD. (1996) Vincristine hyperalgesia in rat: a model of painful vincristine neuropathy in humans. Neuroscience, 73(1), 259–265.
Bhalla S., Singh N., Jaggi AS. (2015) Dose-related neuropathic and anti-neuropathic effects of simvastatin in vincristine-induced neuropathic pain in rats. Food and Chemical Toxicology, 80, 32–40.
Caraceni A, De Conno F, Kaasa S, Radbruch L, Hanks G. Update on cancer pain guidelines. J Pain Symptom Manage 2009; 38: e1–3.
Culter ED, Furukawa KT. Neuropathic pain: treatment options report. California HealthCare Fundation. 2006;1–29.
Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19: 1985–91.
Dixon WE. The pharmacology of Cannabis indica. The British Medical Journal. 1899;2:1354–1357.
Ożarowski M, Mikolajczak PŁ, Bogacz A, Bartkowiak-Wieczorek J, Kujawski R, Majchrzycki M, Wielgus K, Seremak-Mrozikiewicz A, Czerny B. Progress in study of Cannabis sativa leaves extracts without psychotropic cannabinoids in animal model of neuropathic pain. Journal of Medical Science, Vol 83, No 4 (2014).
Palazzo E, Luongo Lo, de Novellis V, Rossi F, Maione S. The role of cannabinoid receptors in the descending modulation of pain. Pharmaceuticals 2010; 3, 2661–2673
Palmer SL, Thakur GA, Makriyannis A. Cannabinergic ligands.Chemistry and Physics of Lipids 2002;121:3–19.
Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, Bohlin L. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull. 2011;34(5):774–8.
Russso EB., Cannabinoids in the management of difficult to treat pain., Ther Clin Risk Manag. 2008 Feb;4(1):245–59.
Shi J. (2014) Evaluating the various phases of cisplatin-induced emesis in rats. Oncology Letters, 8, 2017–2022.
Tatsushima Y, Egashira N, Matsushita N, Kurobe K, Kawashiri T, Yano T, Oishi R. (2011) Pemirolast reduces cisplatin-induced kaolin intake in rats. European Journal of Pharmacology, 661, 57–62.
Walker JM, Huang SM. Cannabinoid analgesia. Pharmacology & Therapeutics 2002;95:127– 135.
Wang CZ, Fishbein A, Aung HH, Mehendale SR, Chang WT, Xie JT, Li J, Yuan CS. (2005) Polyphenol contents in grape-seed extracts correlate with antipica effects in cisplatin-treated rats. J Altern Complement Med. 1(6), 1059–1065.